2.27
+0.26(+12.94%)
Currency In USD
Address
1 Commonwealth Lane, No. 08-22
Singapore, 149544
Singapore
Phone
65 6250 7738
Website
Sector
Healthcare
Industry
Biotechnology
Employees
43
First IPO Date
April 14, 2023
| Name | Title | Pay | Year Born |
| Mr. Chee Kong Choo | Executive Chairman | 38,143 | 1958 |
| Dr. Jieming Zeng M.D., Ph.D. | Chief Scientific & Medical Officer and Director | 102,037 | 1974 |
| Ms. Yvonne Goh | Chief Financial Officer | 0 | 1990 |
| Ms. Yoong Ying Tan | Chief Corporate Officer | 0 | 1989 |
| Dr. Tien Wee Luk M.D. | Chief Clinical Officer | 0 | 1986 |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.